6533b82afe1ef96bd128c30d

RESEARCH PRODUCT

Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer

Marco BorghesiGian Maria BusettoGiorgio GuazzoniGilberto L. AlmeidaShahrokh F. ShariatRocco DamianoRoberto La RoccaRiccardo AutorinoRodolfo HurleGiovanni GrimaldiVincenzo MironePierluigi BoveGiuseppe LucarelliPaolo VerzeMihai Dorin VartolomeiFrancesco CantielloSisto PerdonàSavino M. Di StasiMatteo FerroEugenio BrunocillaEttore De BerardinisOttavio De CobelliGiorgio Ivan RussoAbdal Rahman Abu FarhanEstevão LimaNicolae CrisanRiccardo SchiavinaGiuseppe MorgiaDaniela TerraccianoVincenzo SerrettaMichele BattagliaGennaro Musi

subject

High risk; High-grade; NLR; Progression; RecurrenceMaleNeutrophilsmedicine.medical_treatment030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineRecurrenceHigh-gradeRecurrence.LymphocytesHigh risk; High-grade; NLR; Progression; Recurrence; Oncology; UrologyAged 80 and overProgressionHigh riskMiddle AgedPrognosis3. Good healthAdministration IntravesicalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisCohortBCG VaccineDisease ProgressionFemaleNon muscle invasiveAdjuvantAdultmedicine.medical_specialtyUrologyUrologyCystectomyDisease-Free SurvivalNLRResection03 medical and health sciencesmedicineHumansLymphocyte CountNeutrophil to lymphocyte ratioAgedRetrospective StudiesScience & TechnologyBladder cancerbusiness.industryfungimedicine.diseaseConfidence intervalUrinary Bladder NeoplasmsMulticenter studyNeoplasm Recurrence Localbusiness

description

The aim of this multicenter study was to investigate the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and to validate the NLR cutoff of 3 in a large multi-institutional cohort of patients with primary T1 HG/G3 non-muscle-invasive bladder cancer (NMIBC).

yearjournalcountryeditionlanguage
2018-12-01Clinical Genitourinary Cancer
https://doi.org/10.1016/j.clgc.2018.07.003